| 1 |
Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006;116:1744-54.
DOI
ScienceOn
|
| 2 |
Ming M, Li X, Fan X, Yang D, Li L, Chen S, Gu Q, Le W. Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic eff ects of RPE cell transplantation in Parkinson's disease. J Transl Med 2009;7:53.
DOI
ScienceOn
|
| 3 |
Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD; CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
DOI
ScienceOn
|
| 4 |
Frankemolle AM, Wu J, Noecker AM, Voelcker-Rehage C, Ho JC, Vitek JL, McIntyre CC, Alberts JL. Reversing cognitivemotor impairments in Parkinson's disease patients using a computational modelling approach to deep brain stimulation programming. Brain 2010;133(Pt 3):746-61.
DOI
|
| 5 |
Zahodne LB, Okun MS, Foote KD, Fernandez HH, Rodriguez RL, Kirsch-Darrow L, Bowers D. Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. Clin Neuropsychol 2009;23:385-405.
DOI
ScienceOn
|
| 6 |
Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-95.
DOI
ScienceOn
|
| 7 |
Jeon P, Yang S, Jeong H, Kim H. Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction. Anat Cell Biol 2011;44:135-42.
DOI
|
| 8 |
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfi eld H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9.
DOI
ScienceOn
|
| 9 |
Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008;14:507-9.
DOI
ScienceOn
|
| 10 |
Xi J, Zhang SC. Stem cells in development of therapeutics for Parkinson's disease: a perspective. J Cell Biochem 2008;105:1153-60.
DOI
ScienceOn
|
| 11 |
Joyner AL, Liu A, Millet S. Otx2, Gbx2 and Fgf8 interact to position and maintain a mid-hindbrain organizer. Curr Opin Cell Biol 2000;12:736-41.
DOI
ScienceOn
|
| 12 |
Smidt MP, Burbach JP. How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 2007;8:21-32.
DOI
ScienceOn
|
| 13 |
Ono Y, Nakatani T, Sakamoto Y, Mizuhara E, Minaki Y, Kumai M, Hamaguchi A, Nishimura M, Inoue Y, Hayashi H, Takahashi J, Imai T. Diff erences in neurogenic potential in fl oor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic fl oor plate cells. Development 2007;134:3213-25.
DOI
ScienceOn
|
| 14 |
Andersson E, Tryggvason U, Deng Q, Friling S, Alekseenko Z, Robert B, Perlmann T, Ericson J. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 2006;124:393-405.
DOI
ScienceOn
|
| 15 |
Friling S, Andersson E, Thompson LH, Jonsson ME, Hebsgaard JB, Nanou E, Alekseenko Z, Marklund U, Kjellander S, Volakakis N, Hovatta O, El Manira A, Bjorklund A, Perlmann T, Ericson J. Effi cient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci U S A 2009;106:7613-8.
DOI
ScienceOn
|
| 16 |
Rodriguez-Gomez JA, Lu JQ, Velasco I, Rivera S, Zoghbi SS, Liow JS, Musachio JL, Chin FT, Toyama H, Seidel J, Green MV, Thanos PK, Ichise M, Pike VW, Innis RB, McKay RD. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 2007;25:918-28.
DOI
ScienceOn
|
| 17 |
Ko JY, Park CH, Koh HC, Cho YH, Kyhm JH, Kim YS, Lee I, Lee YS, Lee SH. Human embryonic stem cell-derived neural precursors as a continuous, stable, and on-demand source for human dopamine neurons. J Neurochem 2007;103:1417-29.
DOI
ScienceOn
|
| 18 |
Ko JY, Lee HS, Park CH, Koh HC, Lee YS, Lee SH. Conditions for tumor-free and dopamine neuron-enriched grafts after transplanting human ES cell-derived neural precursor cells. Mol Ther 2009;17:1761-70.
DOI
ScienceOn
|
| 19 |
Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, Kim DW. Highly efficient and largescale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A 2008;105:3392-7.
DOI
ScienceOn
|
| 20 |
Jo AY, Kim MY, Lee HS, Rhee YH, Lee JE, Baek KH, Park CH, Koh HC, Shin I, Lee YS, Lee SH. Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant. Stem Cells 2009;27:2238-46.
DOI
ScienceOn
|
| 21 |
Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009;217:318-24.
DOI
ScienceOn
|
| 22 |
Muramatsu S, Okuno T, Suzuki Y, Nakayama T, Kakiuchi T, Takino N, Iida A, Ono F, Terao K, Inoue N, Nakano I, Kondo Y, Tsukada H. Multitracer assessment of dopamine function aft er transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. Synapse 2009;63:541-8.
DOI
ScienceOn
|
| 23 |
Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev 2010;19:1017-23.
DOI
ScienceOn
|
| 24 |
Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011;146:318-31.
DOI
ScienceOn
|
| 25 |
Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509-25.
DOI
ScienceOn
|
| 26 |
Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006;198:54-64.
DOI
ScienceOn
|
| 27 |
Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. J Mol Neurosci 2009;39:199-210.
DOI
ScienceOn
|
| 28 |
Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Off en D. Protective eff ects of neurotrophic factorsecreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 2009;18:1179-90.
DOI
ScienceOn
|
| 29 |
Shetty P, Ravindran G, Sarang S, Thakur AM, Rao HS, Viswanathan C. Clinical grade mesenchymal stem cells transdif fe rentiated under xenofree conditions alleviates motor defi ciencies in a rat model of Parkinson's disease. Cell Biol Int 2009;33:830-8.
DOI
ScienceOn
|
| 30 |
Kim YJ, Park HJ, Lee G, Bang OY, Ahn YH, Joe E, Kim HO, Lee PH. Neuroprotective eff ects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia 2009;57:13-23.
DOI
ScienceOn
|
| 31 |
Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 2008;107:141-51.
DOI
ScienceOn
|
| 32 |
Zou Z, Jiang X, Zhang W, Zhou Y, Ke Y, Zhang S, Xu R. Effi cacy of tyrosine hydroxylase gene modifi ed neural stem cells derived from bone marrow on Parkinson's disease: a rat model study. Brain Res 2010;1346:279-86.
DOI
|
| 33 |
Zhu Q, Ma J, Yu L, Yuan C. Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats. Neurosci Lett 2009;462:213-8.
DOI
ScienceOn
|
| 34 |
Kubo A, Yoshida T, Kobayashi N, Yokoyama T, Mimura T, Nishiguchi T, Higashida T, Yamamoto I, Kanno H. Efficient generation of dopamine neuron-like cells from skin-derived precursors with a synthetic peptide derived from von Hippel-Lindau protein. Stem Cells Dev 2009;18:1523-32.
DOI
ScienceOn
|
| 35 |
Jackson JS, Golding JP, Chapon C, Jones WA, Bhakoo KK. Homing of stem cells to sites of infl ammatory brain injury aft er intracerebral and intravenous administration: a longitudinal imaging study. Stem Cell Res Ther 2010;1:17.
DOI
ScienceOn
|
| 36 |
Yang XX, Xue SR, Dong WL, Kong Y. Therapeutic eff ect of human amniotic epithelial cell transplantation into the lateral ventricle of hemiparkinsonian rats. Chin Med J (Engl) 2009;122:2449-54.
|
| 37 |
Stover NP, Watts RL. Spheramine for treatment of Parkinson's disease. Neurotherapeutics 2008;5:252-9.
DOI
ScienceOn
|
| 38 |
Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, Dagher A, Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005;128(Pt 7):1498-510.
DOI
|
| 39 |
Okano H, Sawamoto K. Neural stem cells: involvement in adult neurogenesis and CNS repair. Philos Trans R Soc Lond B Biol Sci 2008;363:2111-22.
DOI
ScienceOn
|
| 40 |
Grealish S, Jonsson ME, Li M, Kirik D, Bjorklund A, Thompson LH. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010;133(Pt 2):482-95.
DOI
|
| 41 |
Barker RA, Kuan WL. Graft -induced dyskinesias in Parkinson's disease: what is it all about? Cell Stem Cell 2010;7:148-9.
DOI
ScienceOn
|
| 42 |
Placzek MR, Chung IM, Macedo HM, Ismail S, Mortera Blanco T, Lim M, Cha JM, Fauzi I, Kang Y, Yeo DC, Ma CY, Polak JM, Panoskaltsis N, Mantalaris A. Stem cell bioprocessing: fundamentals and principles. J R Soc Interface 2009;6:209-32.
DOI
ScienceOn
|
| 43 |
Watts RL, Gross RE, Hauser RA, Bakay RA, Reichmann H, Stiver NP, Reissig E, Steiner-Schulze H, Fichte K. A phase 2b study evaluating }$} "$Spheramine^{(R)}$") in patients with advanced Parkinson's disease [Internet]. Movement Disorder Virtual University; 2009 [cited 2010 Dec 27]. Available from: http://www.mdvu.org/emove/article.asp?ID=1192.
|
| 44 |
Farag ES, Vinters HV, Bronstein J. Pathologic fi ndings in retinal pigment epithelial cell implantation for Parkinson disease. Neurology 2009;73:1095-102.
DOI
ScienceOn
|
| 45 |
Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002;22:782-90.
|
| 46 |
Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-75.
DOI
ScienceOn
|
| 47 |
Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 2001;316:67-70.
DOI
ScienceOn
|
| 48 |
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-49.
DOI
ScienceOn
|
| 49 |
Th ompson LH, Grealish S, Kirik D, Björklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 2009;30:625-38.
DOI
ScienceOn
|
| 50 |
Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6:e1000029.
DOI
|
| 51 |
Camp DM, Loeffl er DA, Farrah DM, Borneman JN, LeWitt PA. Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease. J Neuroinfl ammation 2009;6:17.
DOI
ScienceOn
|
| 52 |
Politis M. Dyskinesias aft er neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med 2010;8:80.
DOI
ScienceOn
|
| 53 |
Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Role of serotonin neurons in the induction of levodopa- and graftinduced dyskinesias in Parkinson's disease. Mov Disord 2010;25 Suppl 1:S174-9.
|
| 54 |
Lindvall O, Bjorklund A. Cell replacement therapy: helping the brain to repair itself. NeuroRx 2004;1:379-81.
DOI
ScienceOn
|
| 55 |
Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-6.
DOI
ScienceOn
|
| 56 |
Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-3.
DOI
ScienceOn
|
| 57 |
Lee PH, Park HJ. Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy. J Clin Neurol 2009;5:1-10.
|
webmaster
